Author:
Zhou Bing,Cheng Lei,Pan Jing,Wang Huizhong,Jin Yongde,Zhao Changqing,Lin Peng,Tan Guolin,Fang Hongyan,Zhang Hua,Zhou Huifang,Dong Yaowu,Kuhl Hans Christian,Ramalingam Rajesh Kumar,Nguyen Duc Tung
Funder
MEDA Pharma GmbH & Co. KG (a Mylan Company) now Viatris
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine,Respiratory Care
Reference23 articles.
1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008*. Allergy. 2008;63:8–160.
2. Zhang Y, Zhang L. Increasing prevalence of allergic rhinitis in China. Allergy Asthma Immunol Res. 2019;11(2):156–69.
3. Wang X, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71:1170–80. https://doi.org/10.1111/all.12874.
4. Liu G, Zhu R, Wang Z, et al. Assessment of quality of life in allergic rhinitis patients with Chinese version of SF-36. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005;19(12):541–2.
5. Klimek L, Sperl A, Becker S, et al. Current therapeutical strategies for allergic rhinitis. Expert Opinion Pharmacother. 2019;20(1):83–9.